Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

Sanofi’s cancer immunotherapy Libtayo (cemiplimab ... patients whose tumours have high PD-L1 expression brings the drug into competition with Merck & Co’s Keytruda (pembrolizumab), which ...

The approval of Libtayo (cemiplimab) in advanced NSCLC is for first-line treatment of patients with 50% or more PD-L1 expression and no EGFR, ALK or ROS1 aberrations, taking the drug into a large ...

We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc.

What makes the company unique is its advanced VelociSuite technology, which accelerates drug discovery and genetic ... Key products like Dupixent, Libtayo, and EYLEA fueled the company’s growth.

During a Community Case Forum event in partnership with the Texas Society of Clinical Oncology, Natalie Vokes, MD, discussed trials of targeted agents for EGFR-mutant lung cancer.

Researchers found that adherence to the first and second annual screenings was 61% and 51%, respectively, with higher lung ...

Rheumatoid arthritis (RA) treatment usually includes antirheumatic drugs (DMARDs) combined with nonsteroidal anti-inflammatory drugs and low-dose steroids. Steroids are technically called ...

To help you determine what's true, let's discuss apple cider vinegar's possible benefits and side effects, along with the ideal daily dosage. When you combine apples, sugar and yeast and allow ...